GlassScriptPhysician profile
Shoni Jaye Rozenberg
NPI 1902284854
$15,754.77
in general payments reported to CMS, 2019-2025
35 companies · $2,480 in 2025
The $2,480 reported for 2025 was more than what 81% of Dermatology providers received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,192 · 2020: $721 · 2021: $1,922 · 2022: $3,873 · 2023: $3,069 · 2024: $2,498 · 2025: $2,480.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,796 · Education: $252.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,795.68 |
| Education | $251.98 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Galderma Laboratories, L.P. | $1,898.13 | 2020-2025 | Aklief, Nemluvio |
| Abbvie INC. | $1,621.99 | 2019-2025 | Skyrizi, Rinvoq, Botox |
| Epi Health, LLC | $1,506.41 | 2022 | |
| Regeneron Healthcare Solutions, INC. | $1,484.07 | 2019-2025 | Dupixent |
| Genzyme Corporation | $1,209.10 | 2019-2025 | |
| Amgen INC. | $969.41 | 2020-2024 | Otezla |
| Novartis Pharmaceuticals Corporation | $804.37 | 2019-2025 | |
| Janssen Biotech, INC. | $776.41 | 2020-2025 | Tremfya, Remicade, Stelara |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $621.21 | 2019-2025 | Cabtreo, Jublia, Duobrii |
| Lilly USA, LLC | $558.42 | 2019-2025 | Taltz, Olumiant, Ebglyss |
| Pfizer INC. | $485.91 | 2022-2025 | |
| Sun Pharmaceutical Industries INC. | $449.68 | 2021-2024 | Winlevi |
| Dermavant Sciences, INC. | $406.72 | 2022-2024 | Vtama |
| Almirall LLC | $381.62 | 2019-2023 | Seysara, Klisyri |
| Allergan, INC. | $330.30 | 2019-2022 |
Show all 35 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merz North America, INC. | $285.53 | 2022-2025 | Xeomin |
| E.R. Squibb & Sons, L.L.C. | $259.89 | 2022-2024 | Sotyktu |
| Biofrontera INC. | $259.40 | 2021-2025 | Ameluz, Xepi, Bf-Rhodoled |
| Incyte Corporation | $257.46 | 2022-2025 | Opzelura |
| Ucb, INC. | $176.68 | 2021-2025 | Bimzelx |
| Mayne Pharma Commercial LLC | $158.26 | 2019-2025 | |
| Arcutis Biotherapeutics, INC. | $111.72 | 2023-2024 | Zoryve |
| Boehringer Ingelheim Pharmaceuticals, INC. | $108.66 | 2022 | |
| Leo Pharma INC. | $103.44 | 2019-2022 | |
| Verrica Pharmaceuticals INC. | $72.96 | 2023-2025 | Ycanth |
| Sanofi-Aventis U.S. LLC | $72.00 | 2025 | |
| Smith+Nephew, INC. | $63.23 | 2023-2024 | Grafix Pl |
| Revance Therapeutics, INC. | $59.96 | 2024 | Daxxify |
| Celgene Corporation | $54.56 | 2019 | |
| Journey Medical Corporation | $54.08 | 2023-2025 | |
| Dermira, INC. | $41.62 | 2020-2021 | |
| Botanix Sb INC | $38.12 | 2025 | Sofdra |
| Organon LLC | $28.96 | 2025 | Vtama |
| Cipher Pharmaceuticals US LLC | $23.33 | 2025 | Spinosad, Natroba |
| Sandoz INC. | $21.16 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Shoni Rozenberg listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.